Exxel Pharma is working closely with Professor Piomelli’s laboratory at UC Irvine. The collaboration is focused on preclinical and non-GLP development activities, including testing of URB597 and URB937 in different animal models of human disease. One goal of this work is to support additional clinical indications for the company’s two drugs. The company and UC Irvine have several pending STTR grant applications for some of this work.
Exxel Pharma works closely with Kinexum, a regulatory and strategy firm located in the Washington DC area. Kinexum assists the Company with execution of its regulatory and clinical strategy, as well as with strategic positioning of the Company.